Breaking News
Get 45% Off 0
Is it finally time to sell Nvidia ahead of earnings?
Read More

Bruker Inks Deal To Distribute Coronavirus Detection Test

By Zacks Investment ResearchStock MarketsMar 25, 2020 10:04PM ET
www.investing.com/analysis/bruker-inks-deal-to-distribute-coronavirus-detection-test-200519268
Bruker Inks Deal To Distribute Coronavirus Detection Test
By Zacks Investment Research   |  Mar 25, 2020 10:04PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
LH
-0.39%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
DGX
-0.46%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BIO
+1.20%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BRKR
+1.31%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Bruker Corporation (NASDAQ:BRKR) , through the Bruker-Hain Diagnostics division, inked a distribution deal with Primer Design Ltd (UK), a subsidiary of Novacyt SA, to distribute the CE-IVD-marked genesig real-time PCR coronavirus (COVID-2019) assay.

The deal has come into effect from Mar 25, 2020. Bruker-Hain Diagnostics boasts of a portfolio of DNA/RNA extraction and preparation systems and kits.

The agreement would likely make the company a key player in coronavirus diagnosis.

More about the deal

The genesig real-time PCR Coronavirus (COVID-2019) CE-IVD assay is authorized for use on Bruker-Hain Diagnostics GenoXtract (GXT) automated nucleic acid extraction devices with associated extraction kits. The shipping of the test kits to Spain, France, Germany and the U.K. has already begun.

The genesig assay has been verified for respiratory samples (nasopharyngeal swabs, oropharyngeal swabs, sputum) on commonly available laboratory thermocyclers. The kit includes all necessary reagents to deliver upto 96 results in two hours. The genesig assay has been developed for very high specificity for the 2019-nCoV virus strain that is implicated in COVID-19. The genesig test has CE-IVD clearance and is designed for in-vitro diagnostic use in Europe.

Along with its authorized GXT products for nucleic acid extraction, Bruker is now equipped to offer a solution for the diagnosis of the SARS-CoV-2 virus, the pathogen responsible for COVID-19.

Other Companies Working on Coronavirus Testing

Bio-Rad (NYSE:BIO) , through its Exact Diagnostics portfolio, recently launched a SARS CoV-2 Standard to enable laboratory assay validation of COVID-19 testing.

Quest Diagnostics (NYSE:DGX) recently announced that it is set to launch a COVID-19 test service. The test would facilitate the potential detection of nucleic acid in respiratory specimens of patients, who fulfill CDC's clinical criteria for COVID-19 testing.

LabCorp (NYSE:LH) also recently launched the 2019 Novel coronavirus (COVID-19), NAA test, for doctors and other authorized healthcare providers in the United States. The test diagnoses the presence of the underlying virus that causes COVID-19 and should benefit patients, who meet the current guidelines for the evaluation of the disease.

Price Performance

In the past year, the company’s shares have outperformed the industry. The stock has lost 4.6% compared with the industry’s 23% decline.

Zacks Rank

Bruker currently has a Zacks Rank # 3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>



Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report

Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report

Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report

Bruker Corporation (BRKR): Free Stock Analysis Report

Original post

Zacks Investment Research

Bruker Inks Deal To Distribute Coronavirus Detection Test
 

Related Articles

Bruker Inks Deal To Distribute Coronavirus Detection Test

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email